Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Strattera ® (atomoxetine)
This information is intended for UK registered healthcare professionals only in response to your search for information. For current information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk
How to switch from Strattera® (atomoxetine) or discontinue treatment
Here you may find information on switching from Strattera capsules to other formulations containing atomoxetine, or on discontinuing this medicinal product.
Content overview
How to switch to another atomoxetine formulation?
Switch to Strattera oral solution
Pharmacokinetic studies have shown that atomoxetine capsules and oral solution are bioequivalent.1
Switches from Strattera to a generic formulation
Eli Lilly and Company has not studied how to switch from Strattera to a generic atomoxetine formulation. A recommendation is not available and the decision on how to switch remains at the discretion of the prescribing physician.
How to discontinue atomoxetine?
Is dose tapering needed?
In the study programe no distinct withdrawal symptoms have been described. In cases of significant adverse effects, atomoxetine may be stopped abruptly; otherwise the drug may be tapered off over a suitable time period.1
Switches to other treatments
Eli Lilly and Company has not studied the switch from Strattera to other drug treatments for ADHD.
Treatment decision
The decision on how to continue treatment or how to switch remains at the discretion of prescribing physician.
References
1Strattera Summary of Product Characteristics
2Wernicke JF, Adler L, Spencer T, et al. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol. 2004;24(1):30-35. http://dx.doi.org/10.1097/01.jcp.0000104907.75206.c2
3Camporeale A, Upadhyaya H, Ramos-Quiroga JA, et al. Safety and tolerability of atomoxetine hydrochloride in a long-term, placebo-controlled randomized withdrawal study in European and non-European adults with attention-deficit/hyperactivity disorder. Eur J Psychiatry. 2013;27(3):206-224. http://dx.doi.org/10.4321/S0213-61632013000300005
Date of Last Review: 20 February 2023